Nibourel O, Guihard S, Roumier C, Pottier Letter, Terre C, Paquet Good, Peyrouze P, Geffroy S, Quentin S, Alberdi A beneficial, Abdelali RB, Renneville A, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH. Copy-number data recognized the newest prognostic ;31(3):555-564.
Mohamed Have always been, Balsat M, Koering C, Maucort-Boulch D, Boissel Letter, Payen-Homosexual L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri Yards, Tigaud I, Hayette S, Dumontet C, Cros Elizabeth, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet Yards, Ceraulo A good, Mortreux F, Wattel E. Leuk Res. 2017;-28.
Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud Yards, Perilla-Glen An effective, Aljawai Y, Huynh D, Roccaro In the morning, Sacco Good, Capelletti Yards, Detappe A beneficial, Alignani D, Anderson KC, Munshi NC, Prosper 
F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson Va, Michor F, San Miguel JF, Ghobrial I will be. 2017;19(1):218-224.
Minnema MC, Kimby Elizabeth, DSa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis Elizabeth, Kremer S, Fitsiori A good, Simon L, Davi F, Lunn Meters, Castillo JJ, Patterson CJ, Le Garff-Tavernier Yards, Costopoulos Meters, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP. Guideline towards the prognosis, medication and you may impulse criteria for Yahoo-Neel syndrome. Haematologica. 2017;102(1):43-51.
Micol JB, Pastore A beneficial, Inoue D, Duployez N, Kim E, Lee South carolina, Durham BH, Chung Yr, Cho H, Zhang XJ, Yoshimi Good, Krivtsov A beneficial, Koche Roentgen, Solary Age, Sinha A beneficial, Preudhomme C, Abdel-Wahab O. ASXL2 is very important to own haematopoiesis and you can will act as a beneficial haploinsufficient tumour suppressor in the leukemia. Nat Commun. 2017;8:15429.
Mobile Rep
Meunier M, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet M, Wang Y, Faure P, Szymanski G, Duployez Letter, Preudhomme C, Biard D, Polack B, Cahn JY, Moulis JM, Playground S. Reactive clean air species levels handle NF-kappaB activation by the reasonable amount deferasirox inside the erythroid progenitors regarding reduced risk myelodysplastic syndromes. Oncotarget. 2017;8(62):105510-105524.
Manier S, Salem KZ, Park J, Landau Weil, Getz Grams, Ghobrial I am. Genomic difficulty out of several myeloma and its scientific ramifications. Nat Rev Clin Oncol. 2017;14(2):100-113.
Manier S, Powers JT, Sacco A beneficial, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro Was, Daley GQ, Ghobrial Im. The newest LIN28B/let-eight axis are a novel therapeutic pathway during the several myeloma. Leukemia. 2017;31(4):853-860.
Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A great, Roccaro Have always been, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial Im. Prognostic part out of circulating exosomal miRNAs from inside the several myeloma. Bloodstream. 2017;129(17):2429-2436.
TET2 exon 2 missing is a separate good prognostic foundation getting cytogenetically normal severe myelogenous leukemia (AML): TET2 exon 2 skipping within the AML
Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brownish Le, Gray Letter, Bradner J, Whitesell L, Porco JA, Jr., Ghobrial Im. Inhibiting the new oncogenic translation program is an effectual healing approach within the multiple myeloma. Sci Transl Med. 2017;9(389).
Magnez Roentgen, Thiroux B, Taront S, Segaoula Z, Quesnel B, Thuru X. PD-1/PD-L1 joining studies using microscale thermophoresis. Sci Associate. 2017;7(1):17623.
Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, Feuillard J, Genevieve F, Guerin Age, Child J, Jouault H, Lepelley P, Maynadie Meters, Solly F, Ballon OW, Preudhomme C, Baruchel A great, Dombret H, Ifrah Letter, Bene MC. Prognostic property value multicenter circulate cytometry harmonized analysis regarding restricted residual disease inside severe myeloblastic leukemia. Hematol Oncol. 2017.